Literature DB >> 10867973

Anatomical and pharmacological specificity of the rewarding effect elicited by microinjections of morphine into the nucleus accumbens of mice.

V David1, P Cazala.   

Abstract

RATIONALE: The involvement of nucleus accumbens (NAc) in initiating opiate-induced reward has been difficult to demonstrate in rats, and has not been studied in mice.
OBJECTIVES: To determine whether a reward-sensitive strain of mice (BALB/c) would self-administer morphine directly into the NAc or sub-regions of the dorsal striatum.
METHODS: BALB/c mice were unilaterally implanted with a guide-cannula above either the NAc, the anterior caudate putamen, or the posterior caudate putamen. On each experimental day, a stainless-steel injection cannula was inserted into the guide cannula to test the capacity for morphine self-administration (6.5 pmol or 65 pmol/50 nl) using a spatial discrimination task in a Y maze.
RESULTS: Only the ventro-medial NAc group discriminated between the arm enabling a microinjection of morphine and the neutral arm. Once self-administration had been acquired, the effects of a pretreatment with two doses of the opiate antagonist naloxone (0.4 mg/kg or 4 mg/kg) were tested. Both doses slightly disrupted self-administration on the first 2 days. Only subjects receiving the 4-mg/kg dose exhibited an extinction of self-administration, related to an increasing number of jump attempts; none of the other opiate withdrawal-associated signs were observed. Self-administration was reinstated when naloxone was replaced with saline.
CONCLUSIONS: (1) Medio-ventral NAc is involved in acute rewarding effects of opiates in mice. (2) Neither anterior nor posterior dorsal striatum seem to participate in these effects. (3) NAc is involved in jumping caused by naloxone-induced extinction, a behavior presumably revealing an aversive state associated with the unexpected suppression of reward.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10867973     DOI: 10.1007/s002130000425

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  12 in total

Review 1.  Opioid-induced rewards, locomotion, and dopamine activation: A proposed model for control by mesopontine and rostromedial tegmental neurons.

Authors:  Stephan Steidl; David I Wasserman; Charles D Blaha; John S Yeomans
Journal:  Neurosci Biobehav Rev       Date:  2017-09-23       Impact factor: 8.989

2.  Potential Involvement of a Substantia Nigra Circuit in Opioid Reinforcement.

Authors:  Robert J Oliver
Journal:  J Neurosci       Date:  2021-05-12       Impact factor: 6.167

Review 3.  Understanding opioid reward.

Authors:  Howard L Fields; Elyssa B Margolis
Journal:  Trends Neurosci       Date:  2015-01-29       Impact factor: 13.837

4.  Brain stimulation and morphine reward deficits in dopamine D2 receptor-deficient mice.

Authors:  G I Elmer; J O Pieper; J Levy; M Rubinstein; M J Low; D K Grandy; R A Wise
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

5.  Mouse strain differences in opiate reward learning are explained by differences in anxiety, not reward or learning.

Authors:  C L Dockstader; D van der Kooy
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

Review 6.  How addictive drugs disrupt presynaptic dopamine neurotransmission.

Authors:  David Sulzer
Journal:  Neuron       Date:  2011-02-24       Impact factor: 17.173

Review 7.  Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu-opioid receptor.

Authors:  Jia-Jia Zhang; Chang-Geng Song; Ji-Min Dai; Ling Li; Xiang-Min Yang; Zhi-Nan Chen
Journal:  MedComm (2020)       Date:  2022-06-22

Review 8.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

Review 9.  It's MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system.

Authors:  Elena H Chartoff; Hilary S Connery
Journal:  Front Pharmacol       Date:  2014-05-27       Impact factor: 5.810

Review 10.  Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges.

Authors:  Ewa Galaj; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neurosci Biobehav Rev       Date:  2020-05-03       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.